tiprankstipranks
Trending News
More News >

CanSino Biologics Reports Q1 2025 Financial Results with Increased Revenue

Story Highlights
CanSino Biologics Reports Q1 2025 Financial Results with Increased Revenue

Don’t Miss TipRanks’ Half-Year Sale

CanSino Biologics, Inc. Class H ( (HK:6185) ) just unveiled an update.

CanSino Biologics Inc. reported its unaudited financial results for the first quarter of 2025, showing a 20.02% increase in operating revenue compared to the same period last year. Despite the revenue growth, the company experienced a net loss attributable to shareholders, although significantly reduced from the previous year’s loss, indicating a potential improvement in financial health. The report highlights the company’s ongoing challenges in achieving profitability, yet suggests a positive trend in revenue generation.

More about CanSino Biologics, Inc. Class H

CanSino Biologics Inc. is a biotechnology company based in China, focusing on the development and production of innovative vaccines for infectious diseases. The company operates within the pharmaceutical industry and is listed on the Hong Kong Stock Exchange.

YTD Price Performance: -3.02%

Average Trading Volume: 1,674,837

Technical Sentiment Signal: Sell

Current Market Cap: HK$9.37B

For an in-depth examination of 6185 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1